Scientific

MK5 Microarray Data

Affected Genes - Ontology Breakdown - Gene Enrichment - Proteome Analysis

These are the micro-array results of a differential gene expression microarray experiments and the subsequent analysis steps performed on them. The up/down- regulation ratio was obtained by measuring WT cells against MK5 activated cells. See material and methods for technical information as well as the data usage policy.

MK5 Proteome Analysis

Table 3: Type II network, divided ranks. This table presents the output of the simulation of a type-II network in which we relied on the high confidence interactions and micro-array results. The output of the micro-array was then ranked and these ranks used as input into the network simulation. After performing two such simulations (one for the MK5 off and one for the MK5 on microarray output), we divided the ranks and sorted the results accordingly. The output of this technique is a collection of proteins that cluster naturally together.


Navigation/Query Panel:
Click on the attribute name to hide/unhide it. The green arrows can be used to shift columns left/right. Exact word match is written as =..., regular expressions can be matched with ~.... To select all values larger or equal than use >.... This would be <... for values smaller or equal than. To select all values within a specific range use [...,...].
Rank Gene Hugo Network Comparison Type description Value Type Interaction Map Filtered red green network_comparison
Results: HTML CSV LaTeX Showing element 1751 to 1800 of 8289 in total 
Network Comparison Type: Divided
Value Type: Ranked
Filtered: 1

\def\wcA{0.125\textwidth}
\def\wcB{0.125\textwidth}
\def\wcC{0.125\textwidth}
\def\wcD{0.125\textwidth}
\def\wcE{0.125\textwidth}
\def\wcF{0.125\textwidth}
\def\wcG{0.125\textwidth}
\begin{longtable}{|c|c|c|c|c|c|c|}
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Rank\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
Hugo\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
description\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
Interaction Map\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
red\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
green\vspace{3pt}}&\parbox{\wcG}{\vspace{3pt}\noindent
network\_comparison\vspace{3pt}}\\
\hline
\hline
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
876\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
BBOX1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
gamma-butyrobetaine,2-oxoglutarate dioxygenase (ec 1.14.11.1) (gamma-butyrobetaine hydroxylase) (gamma-bbh). [source:swissprot;acc:o75936]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
Low confidence\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
203.744\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
198.658\vspace{3pt}}&\parbox{\wcG}{\vspace{3pt}\noindent
1.0256\vspace{3pt}}\\\cline{2-7}
&\parbox{\wcB}{\vspace{3pt}\noindent
PRKAA1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5'-amp-activated protein kinase, catalytic alpha-1 chain (ec 2.7.1.-) (ampk alpha-1 chain). [source:swissprot;acc:q13131]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
High confidence\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
212.002\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
203.954\vspace{3pt}}&\parbox{\wcG}{\vspace{3pt}\noindent
1.03946\vspace{3pt}}\\\hline
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
877\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
DHX35\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
probable atp-dependent helicase ddx35 (deah-box protein 35). [source:swissprot;acc:q9h5z1]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
Low confidence\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
205.571\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
200.44\vspace{3pt}}&\parbox{\wcG}{\vspace{3pt}\noindent
1.0256\vspace{3pt}}\\\cline{2-7}
&\parbox{\wcB}{\vspace{3pt}\noindent
PRKAB2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5'-amp-activated protein kinase, beta-2 subunit (ampk beta-2 chain). [source:swissprot;acc:o43741]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
High confidence\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
212.002\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
203.954\vspace{3pt}}&\parbox{\wcG}{\vspace{3pt}\noindent
1.03946\vspace{3pt}}\\\hline
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
878\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
ATP11A\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
potential phospholipid-transporting atpase ih (ec 3.6.3.1) (atpase class i type 11a) (atpase is). [source:swissprot;acc:p98196]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
Low confidence\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
203.744\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
198.658\vspace{3pt}}&\parbox{\wcG}{\vspace{3pt}\noindent
1.0256\vspace{3pt}}\\\cline{2-7}
&\parbox{\wcB}{\vspace{3pt}\noindent
PRKAG3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5'-amp-activated protein kinase, gamma-3 subunit (ampk gamma-3 chain) (ampk gamma3). [source:swissprot;acc:q9ugi9]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
High confidence\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
212.002\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
203.954\vspace{3pt}}&\parbox{\wcG}{\vspace{3pt}\noindent
1.03946\vspace{3pt}}\\\hline
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
879\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
3-hydroxyisobutyryl-coenzyme a hydrolase. [source:refseq;acc:nm\_014362]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
Low confidence\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
203.354\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
198.284\vspace{3pt}}&\parbox{\wcG}{\vspace{3pt}\noindent
1.02557\vspace{3pt}}\\\cline{2-7}
&\parbox{\wcB}{\vspace{3pt}\noindent
PRKAB1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5'-amp-activated protein kinase, beta-1 subunit (ampk beta-1 chain) (ampkb). [source:swissprot;acc:q9y478]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
High confidence\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
212.002\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
203.954\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcG}{\vspace{3pt}\noindent
1.03946\vspace{3pt}}}\\\cline{1-3}
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
880\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
PRKAG2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5'-amp-activated protein kinase, gamma-2 subunit (ampk gamma-2 chain) (ampk gamma2) (h91620p). [source:swissprot;acc:q9ugj0]\vspace{3pt}}&&&&\\\cline{2-7}
&\parbox{\wcB}{\vspace{3pt}\noindent
RRM2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
ribonucleoside-diphosphate reductase m2 chain (ec 1.17.4.1) (ribonucleotide reductase small chain). [source:swissprot;acc:p31350]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
Low confidence\vspace{3pt}}}&\parbox{\wcE}{\vspace{3pt}\noindent
201.49\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
196.469\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcG}{\vspace{3pt}\noindent
1.02556\vspace{3pt}}}\\\cline{1-3}\cline{5-6}
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
881\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
MAX\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
max protein. [source:swissprot;acc:p25912]\vspace{3pt}}&&\parbox{\wcE}{\vspace{3pt}\noindent
204.973\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
199.865\vspace{3pt}}&\\\cline{2-7}
&\parbox{\wcB}{\vspace{3pt}\noindent
MYCL1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
l-myc-1 proto-oncogene protein. [source:swissprot;acc:p12524]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
High confidence\vspace{3pt}}}&\parbox{\wcE}{\vspace{3pt}\noindent
227.604\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
219.001\vspace{3pt}}&\parbox{\wcG}{\vspace{3pt}\noindent
1.03928\vspace{3pt}}\\\cline{1-3}\cline{5-7}
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
882\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
MYCN\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
n-myc proto-oncogene protein. [source:swissprot;acc:p04198]\vspace{3pt}}&&\parbox{\wcE}{\vspace{3pt}\noindent
227.601\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
219.008\vspace{3pt}}&\parbox{\wcG}{\vspace{3pt}\noindent
1.03924\vspace{3pt}}\\\cline{2-7}
&\parbox{\wcB}{\vspace{3pt}\noindent
STX1A\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
syntaxin 1a (neuron-specific antigen hpc-1). [source:swissprot;acc:q16623]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
Low confidence\vspace{3pt}}}&\parbox{\wcE}{\vspace{3pt}\noindent
210.979\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
205.723\vspace{3pt}}&\parbox{\wcG}{\vspace{3pt}\noindent
1.02555\vspace{3pt}}\\\cline{1-3}\cline{5-7}
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
883\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
nadh-ubiquinone oxidoreductase mlrq subunit (ec 1.6.5.3) (ec 1.6.99.3) (complex i-mlrq) (ci-mlrq). [source:swissprot;acc:o00483]\vspace{3pt}}&&\parbox{\wcE}{\vspace{3pt}\noindent
202.572\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
197.533\vspace{3pt}}&\parbox{\wcG}{\vspace{3pt}\noindent
1.02551\vspace{3pt}}\\\cline{2-7}
&\parbox{\wcB}{\vspace{3pt}\noindent
GABPA\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
ga binding protein alpha chain (gabp-alpha subunit) (transcription factor e4tf1-60) (nuclear respiratory factor-2 subunit alpha). [source:swissprot;acc:q06546]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
High confidence\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
227.596\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
219.017\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcG}{\vspace{3pt}\noindent
1.03917\vspace{3pt}}}\\\cline{1-3}
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
884\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
ga binding protein beta-2 chain (gabp-beta-2 subunit) (transcription factor e4tf1-47) (gapbp-2) (nuclear respiratory factor-2 subunit gamma). [source:swissprot;acc:q06545]\vspace{3pt}}&&&&\\\cline{2-7}
&\parbox{\wcB}{\vspace{3pt}\noindent
NDUFA4L2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
nadh:ubiquinone oxidoreductase mlrq subunit homolog (nuoms). [source:swissprot;acc:q9nrx3]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
Low confidence\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
202.572\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
197.533\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcG}{\vspace{3pt}\noindent
1.02551\vspace{3pt}}}\\\cline{1-3}
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
885\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
CDC5L\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
cdc5-like; cdc5 (cell division cycle 5, s. pombe, homolog)-like; cell division cycle 5, s. pombe, homolog-like; cdc5-related protein. [source:refseq;acc:nm\_001253]\vspace{3pt}}&&&&\\\cline{2-7}
&\parbox{\wcB}{\vspace{3pt}\noindent
NDUFS8\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
nadh-ubiquinone oxidoreductase 23 kda subunit, mitochondrial precursor (ec 1.6.5.3) (ec 1.6.99.3) (complex i-23kd) (ci-23kd) (tyky subunit). [source:swissprot;acc:o00217]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
High confidence\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
227.596\vspace{3pt}}}&\parbox{\wcF}{\vspace{3pt}\noindent
219.017\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcG}{\vspace{3pt}\noindent
1.03917\vspace{3pt}}}\\\cline{1-3}\cline{6-6}
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
886\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
ELOVL1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
elongation of very long chain fatty acids protein 1 (cgi-88). [source:swissprot;acc:q9bw60]\vspace{3pt}}&&&\parbox{\wcF}{\vspace{3pt}\noindent
219.018\vspace{3pt}}&\\\cline{2-7}
&\parbox{\wcB}{\vspace{3pt}\noindent
LIG4\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
dna ligase iv (ec 6.5.1.1) (polydeoxyribonucleotide synthase [atp]). [source:swissprot;acc:p49917]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
Low confidence\vspace{3pt}}}&\parbox{\wcE}{\vspace{3pt}\noindent
202.568\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
197.535\vspace{3pt}}&\parbox{\wcG}{\vspace{3pt}\noindent
1.02548\vspace{3pt}}\\\cline{1-3}\cline{5-7}
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
887\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
EIF4E\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
eukaryotic translation initiation factor 4e (eif-4e) (eif4e) (mrna cap-binding protein) (eif-4f 25 kda subunit). [source:swissprot;acc:p06730]\vspace{3pt}}&&\parbox{\wcE}{\vspace{3pt}\noindent
202.277\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
197.255\vspace{3pt}}&\parbox{\wcG}{\vspace{3pt}\noindent
1.02546\vspace{3pt}}\\\cline{2-7}
&\parbox{\wcB}{\vspace{3pt}\noindent
TBL3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
transducin beta-like 3; wd-repeat protein sazd. [source:refseq;acc:nm\_006453]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
High confidence\vspace{3pt}}}&\parbox{\wcE}{\vspace{3pt}\noindent
244.155\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
234.96\vspace{3pt}}&\parbox{\wcG}{\vspace{3pt}\noindent
1.03913\vspace{3pt}}\\\cline{1-3}\cline{5-7}
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
888\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
nascent-polypeptide-associated complex alpha polypeptide. [source:refseq;acc:nm\_005594]\vspace{3pt}}&&\parbox{\wcE}{\vspace{3pt}\noindent
212.027\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
204.05\vspace{3pt}}&\parbox{\wcG}{\vspace{3pt}\noindent
1.03909\vspace{3pt}}\\\cline{2-7}
&\parbox{\wcB}{\vspace{3pt}\noindent
EIF4EBP2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
eukaryotic translation initiation factor 4e binding protein 2; eukaryotic translation initiation factor-4e binding protein-1. [source:refseq;acc:nm\_004096]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
Low confidence\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
202.277\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
197.255\vspace{3pt}}&\parbox{\wcG}{\vspace{3pt}\noindent
1.02546\vspace{3pt}}\\\hline
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
889\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
alpha-nac protein. [source:sptrembl;acc:q9h009]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
High confidence\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
212.028\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
204.053\vspace{3pt}}&\parbox{\wcG}{\vspace{3pt}\noindent
1.03908\vspace{3pt}}\\\cline{2-7}
&\parbox{\wcB}{\vspace{3pt}\noindent
ANKHD1-EIF4EBP3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
eukaryotic translation initiation factor 4e binding protein 3; eukaryotic initiation factor 4e-binding protein 3. [source:refseq;acc:nm\_003732]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
Low confidence\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
202.277\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
197.255\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcG}{\vspace{3pt}\noindent
1.02546\vspace{3pt}}}\\\cline{1-3}
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
890\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
BAIAP3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
bai1-associated protein 3; bai-associated protein 3. [source:refseq;acc:nm\_003933]\vspace{3pt}}&&&&\\\cline{2-7}
&\parbox{\wcB}{\vspace{3pt}\noindent
STX7\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
syntaxin 7. [source:swissprot;acc:o15400]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
High confidence\vspace{3pt}}}&\parbox{\wcE}{\vspace{3pt}\noindent
217.181\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
209.012\vspace{3pt}}&\parbox{\wcG}{\vspace{3pt}\noindent
1.03908\vspace{3pt}}\\\cline{1-3}\cline{5-7}
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
891\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
DIRAS1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
small gtp-binding tumor suppressor 1. [source:refseq;acc:nm\_145173]\vspace{3pt}}&&\parbox{\wcE}{\vspace{3pt}\noindent
212.028\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
204.055\vspace{3pt}}&\parbox{\wcG}{\vspace{3pt}\noindent
1.03907\vspace{3pt}}\\\cline{2-7}
&\parbox{\wcB}{\vspace{3pt}\noindent
ETF1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
eukaryotic peptide chain release factor subunit 1 (erf1) (eukaryotic release factor 1) (tb3-1) (c11 protein). [source:swissprot;acc:p46055]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
Low confidence\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
203.493\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
198.443\vspace{3pt}}&\parbox{\wcG}{\vspace{3pt}\noindent
1.02545\vspace{3pt}}\\\hline
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
892\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
DIRAS2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
di-ras2. [source:refseq;acc:nm\_017594]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
High confidence\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
212.028\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
204.055\vspace{3pt}}&\parbox{\wcG}{\vspace{3pt}\noindent
1.03907\vspace{3pt}}\\\cline{2-7}
&\parbox{\wcB}{\vspace{3pt}\noindent
TSC1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
hamartin (tuberous sclerosis 1 protein). [source:swissprot;acc:q92574]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
Low confidence\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
202.488\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
197.465\vspace{3pt}}&\parbox{\wcG}{\vspace{3pt}\noindent
1.02544\vspace{3pt}}\\\hline
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
893\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
MYC\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
myc proto-oncogene protein (c-myc). [source:swissprot;acc:p01106]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
High confidence\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
227.585\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
219.037\vspace{3pt}}&\parbox{\wcG}{\vspace{3pt}\noindent
1.03903\vspace{3pt}}\\\cline{2-7}
&\parbox{\wcB}{\vspace{3pt}\noindent
RRM2B\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
ribonucleotide reductase m2 b (tp53 inducible); p53-inducible ribonucleotide reductase small subunit 2 homolog. [source:refseq;acc:nm\_015713]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
Low confidence\vspace{3pt}}}&\parbox{\wcE}{\vspace{3pt}\noindent
201.434\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
196.441\vspace{3pt}}&\parbox{\wcG}{\vspace{3pt}\noindent
1.02542\vspace{3pt}}\\\cline{1-3}\cline{5-7}
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
894\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
rab gdp dissociation inhibitor alpha (rab gdi alpha) (gdi-1) (xap-4) (oligophrenin 2). [source:swissprot;acc:p31150]\vspace{3pt}}&&\parbox{\wcE}{\vspace{3pt}\noindent
204.25\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
199.19\vspace{3pt}}&\parbox{\wcG}{\vspace{3pt}\noindent
1.0254\vspace{3pt}}\\\cline{2-7}
&\parbox{\wcB}{\vspace{3pt}\noindent
FARSA\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
phenylalanyl-trna synthetase alpha chain (ec 6.1.1.20) (phenylalanine- -trna ligase alpha chain) (phers) (cml33). [source:swissprot;acc:q9y285]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
High confidence\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
217.491\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
209.323\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcG}{\vspace{3pt}\noindent
1.03902\vspace{3pt}}}\\\cline{1-3}
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
895\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
FARS2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
phenylalanine-trna synthetase. [source:refseq;acc:nm\_006567]\vspace{3pt}}&&&&\\\cline{2-7}
&\parbox{\wcB}{\vspace{3pt}\noindent
GLRX2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
glutaredoxin 2; cgi-133 protein. [source:refseq;acc:nm\_016066]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
Low confidence\vspace{3pt}}}&\parbox{\wcE}{\vspace{3pt}\noindent
203.861\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
198.812\vspace{3pt}}&\parbox{\wcG}{\vspace{3pt}\noindent
1.0254\vspace{3pt}}\\\cline{1-3}\cline{5-7}
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
896\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
COL6A2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
collagen alpha 2(vi) chain precursor. [source:swissprot;acc:p12110]\vspace{3pt}}&&\parbox{\wcE}{\vspace{3pt}\noindent
205.315\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
200.235\vspace{3pt}}&\parbox{\wcG}{\vspace{3pt}\noindent
1.02537\vspace{3pt}}\\\cline{2-7}
&\parbox{\wcB}{\vspace{3pt}\noindent
POLR2J\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
dna-directed rna polymerase ii 13.3 kda polypeptide (ec 2.7.7.6) (rpb11). [source:swissprot;acc:p52435]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
High confidence\vspace{3pt}}}&\parbox{\wcE}{\vspace{3pt}\noindent
230.811\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
239.785\vspace{3pt}}&\parbox{\wcG}{\vspace{3pt}\noindent
1.03888\vspace{3pt}}\\\cline{1-3}\cline{5-7}
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
897\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
PDPK1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
3-phosphoinositide dependent protein kinase-1 (ec 2.7.1.37) (hpdk1). [source:swissprot;acc:o15530]\vspace{3pt}}&&\parbox{\wcE}{\vspace{3pt}\noindent
272.878\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
283.472\vspace{3pt}}&\parbox{\wcG}{\vspace{3pt}\noindent
1.03882\vspace{3pt}}\\\cline{2-7}
&\parbox{\wcB}{\vspace{3pt}\noindent
PES1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
pescadillo homolog 1. [source:swissprot;acc:o00541]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
Low confidence\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
202.55\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
197.54\vspace{3pt}}&\parbox{\wcG}{\vspace{3pt}\noindent
1.02536\vspace{3pt}}\\\hline
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
898\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
60s acidic ribosomal protein p1. [source:swissprot;acc:p05386]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
High confidence\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
229.171\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
238.048\vspace{3pt}}&\parbox{\wcG}{\vspace{3pt}\noindent
1.03874\vspace{3pt}}\\\cline{2-7}
&\parbox{\wcB}{\vspace{3pt}\noindent
WAS\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
wiskott-aldrich syndrome protein (wasp). [source:swissprot;acc:p42768]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
Low confidence\vspace{3pt}}}&\parbox{\wcE}{\vspace{3pt}\noindent
198.379\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
193.474\vspace{3pt}}&\parbox{\wcG}{\vspace{3pt}\noindent
1.02535\vspace{3pt}}\\\cline{1-3}\cline{5-7}
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
899\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
KYNU\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
kynureninase (ec 3.7.1.3) (l-kynurenine hydrolase). [source:swissprot;acc:q16719]\vspace{3pt}}&&\parbox{\wcE}{\vspace{3pt}\noindent
190.965\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
186.246\vspace{3pt}}&\parbox{\wcG}{\vspace{3pt}\noindent
1.02534\vspace{3pt}}\\\cline{2-7}
&\parbox{\wcB}{\vspace{3pt}\noindent
TXNDC2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
thioredoxin domain-containing 2; sperm-specific thioredoxin; thioredoxin domain-containing 2 (spermatozoa). [source:refseq;acc:nm\_032243]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
High confidence\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
229.171\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
238.048\vspace{3pt}}&\parbox{\wcG}{\vspace{3pt}\noindent
1.03874\vspace{3pt}}\\\hline
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
900\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
RHD\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
blood group rh(d) polypeptide (rhesus d antigen) (rhxiii) (rh polypeptide 2) (rhpii). [source:swissprot;acc:q02161]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
Low confidence\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
201.015\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
196.054\vspace{3pt}}&\parbox{\wcG}{\vspace{3pt}\noindent
1.0253\vspace{3pt}}\\\cline{2-7}
&\parbox{\wcB}{\vspace{3pt}\noindent
TXN\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
thioredoxin (atl-derived factor) (adf) (surface associated sulphydryl protein) (sasp). [source:swissprot;acc:p10599]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
High confidence\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
229.171\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
238.048\vspace{3pt}}&\parbox{\wcG}{\vspace{3pt}\noindent
1.03874\vspace{3pt}}\\\hline
nd{longtable}

Legend:
- Rank is the rank after comparing the two networks

 - Gene is the ensembl human gene identifier measured by 1 or more probes on the microarray

 - Hugo is the HGNC identifier if it exists

 - Value Type describes how the microarray measurement was processed. Ranked indicates that we sorted all measurements and use the rank as red and green value. Measured is the normal measurement. Squared and Rooted are the square and square root respecitcely. This might be valueable to compensate for non linear light distributions.

 - Network Comparison Type describes whether we divided the red and green types or whether we sutractcted them

 - Interaction Map specifies whether we used only the hig hconfidence protein-protein interactions or also included the low confidence interactions.

 - Filtered specifies whether we only included the high confidence microarry measurements or not.
- http://analysis.yellowcouch.org/